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Abstract 17 
This work evaluates the biodegradation of the antiviral drug acyclovir by an enriched 18 
nitrifying culture during ammonia oxidation and without the addition of ammonium. The study 19 
on kinetics was accompanied with the structural elucidation of biotransformation products 20 
through batch biodegradation experiments at two different initial levels of acyclovir (15 mg L-1 21 
and 15 µg L-1). The pseudo first order kinetic studies of acyclovir in the presence of ammonium 22 
indicated the higher degradation rates under higher ammonia oxidation rates than those constant 23 
degradation rates in the absence of ammonium. The positive correlation was found between 24 
acyclovir degradation rate and ammonia oxidation rate, confirming the cometabolism of 25 
acyclovir by the enriched nitrifying culture in the presence of ammonium. Formation of the 26 
product carboxy-acyclovir (P239) indicated the main biotransformation pathway was aerobic 27 
oxidation of the terminal hydroxyl group, which was independent on the metabolic type (i.e. 28 
cometabolism or metabolism). This enzyme-linked reaction might be catalyzed by 29 
monooxygenase from ammonia oxidizing bacteria or heterotrophs. The formation of carboxy-30 
acyclovir was demonstrated to be irrelevant to the acyclovir concentrations applied, indicating 31 
the revealed biotransformation pathway might be the dominant removal pathway of acyclovir in 32 
wastewater treatment. 33 
 34 
Keywords: Biotransformation; nitrification; cometabolism; ammonia oxidizing bacteria; 35 
acyclovir; wastewater treatment. 36 
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1. Introduction 38 
In recent years, the increasing concerns have been focused on the emerging pharmaceuticals 39 
in aquatic environment due to their potential hazardous effects on living organisms (Daughton 40 
and Ternes, 1999; Kümmerer, 2009; Sirés and Brillas, 2012). Large amounts of pharmaceuticals 41 
were used by human beings or manufactured for veterinary drugs, leading to their widespread 42 
occurrence in the wastewater, surface water and ground water (Luo et al., 2014). Wastewater 43 
treatment plant (WWTP) was an important pathway for pharmaceuticals entering into the 44 
environment (Kosma et al., 2010; Tijani et al., 2013). Inefficient removal efficiencies of these 45 
compounds were observed during treatment processes because WWTPs were mainly designed 46 
for bulk nutrient removal (Joss et al., 2006; Kosma et al., 2014; Ternes, 1998). 47 
Nitrification process was observed to be able to enhance the removal of pharmaceuticals 48 
(Batt et al., 2006; Fernandez-Fontaina et al., 2012). The involved ammonia oxidizing bacteria 49 
(AOB) were probably responsible for cometabolic biodegradation of pharmaceuticals due to its 50 
non-specific enzyme ammonia monooxygenase (AMO), which was confirmed to degrade a 51 
broad range of organic substrates including aliphatic and aromatic compounds (Keener and Arp, 52 
1994; Lauchnor and Semprini, 2013; Rasche et al., 1990; Skotnicka-Pitak et al., 2009). 53 
Furthermore, biotransformation products formed during treatment processes may be more 54 
persistent and could probably contribute to the overall toxicity (Miao and Metcalfe, 2003; Pérez 55 
et al., 2006; Quintana et al., 2005; Ternes et al., 2007). Therefore, the biotransformation products 56 
should also be considered in order to get a comprehensive understanding of the behavior and fate 57 
of pharmaceuticals in the environment and engineered systems. 58 
As an important antiviral drug, acyclovir has been consumed largely especially for influenza 59 
epidemics. Due to their potential ecosystem alterations and the development of viral resistances, 60 
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antiviral drugs have recently attracted the interest of research. For example, a substantial removal 61 
(98%) of acyclovir was found in the wastewater treatment with the concentration decreasing 62 
from 1780 ng L-1 to 27 ng L-1 (Prasse et al., 2010). Although lab-scale biodegradation of 63 
acyclovir was previously studied by the activated sludge from the nitrification zone of a real 64 
wastewater treatment plant (Prasse et al., 2011), the effect of metabolic conditions on the 65 
formation of biotransformation products and the specific contributions of AOB and heterotrophs 66 
to acyclovir removal has not been clearly defined so far. 67 
This study aims to investigate the biodegradation kinetics, products and pathways of 68 
acyclovir by an enriched nitrifying culture through batch biodegradation experiments under 69 
different metabolic conditions, i.e., with and without the addition of growth substrate, 70 
ammonium. The kinetic analysis was accompanied with the structural elucidation of 71 
biotransformation products. The initial acyclovir concentration at 15 mg L-1 and 15 µg L-1 were 72 
applied to verify if the biotransformation products and pathways formed under high 73 
concentration would occur at environmentally relevant levels. 74 
 75 
2. Materials and Methods 76 
 77 
2.1 Chemicals 78 
Acyclovir (>98%) was purchased from Thermo Fisher, Australia. Carboxy-acyclovir was 79 
provided by Toronto Research Chemicals. Isotope labeled compound acyclovir-d4 was obtained 80 
from Santa Cruz Biotechnology. HPLC grade organic solvents (methanol, acetonitrile, hexane 81 
and acetone) were supplied by Sigma-Aldrich, Australia. The individual standard stock solution 82 
of acyclovir was prepared on a weight basis in methanol at 1 mg mL-1 and stored at -20 °C. The 83 
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calibration curve was obtained by diluting the stock solution appropriately in methanol/water 84 
(25:75, v/v). Acyclovir feed solution used in the batch experiments was prepared in Milli-Q 85 
water (Millipore, Inc.) at initial concentration of 1 g L-1. 86 
 87 
2.2 Enriched nitrifying culture 88 
An 8-L lab-scale sequencing batch reactor (SBR) was inoculated with the activated sludge 89 
from a domestic wastewater treatment plant in Brisbane, Australia. It was operated with the aim 90 
for the enrichment of nitrifying culture (containing AOB and nitrite oxidizing bacteria (NOB) to 91 
perform full nitrification) in cycles of 6 h. For each cycle, it consisted of aerobic feeding (260 92 
min), aeration (30 min), waste (1 min), settling (60 min) and decanting (9 min). 2 L synthetic 93 
wastewater consisting of 1 g L-1 NH4+-N was fed into the reactor during each feeding period, 94 
resulting in a hydraulic retention time (HRT) of 24 h. The solid retention time (SRT) was 95 
controlled at around 15 d. Dissolved oxygen (DO) was controlled between 2.5-3.0 mg L-1 using 96 
programmed logic controllers (PLC) and pH was maintained at the range of 7.5-8.0.  97 
The synthetic wastewater for the enriching the nitrifying culture contained per liter (Kuai 98 
and Verstraete, 1998): 5.63 g of NH4HCO3 (1 g NH4+-N), 5.99 g of NaHCO3, 0.064 g of each of 99 
KH2PO4 and K2HPO4 and 2 mL of a trace element solution. The trace element stock solution 100 
contained: 1.25 g L-1 EDTA, 0.55 g L-1 ZnSO4·7H2O, 0.40 g L-1 CoCl2·6H2O, 1.275 g L-1 101 
MnCl2·4H2O, 0.40 g L-1 CuSO4·5H2O, 0.05 g L-1 Na2MoO4·2H2O, 1.375 g L-1 CaCl2·2H2O, 1.25 102 
g L-1 FeCl3·6H2O and 44.4 g L-1 MgSO4·7H2O. 103 
The biodegradation experiments in this study were conducted after more than 1 year of 104 
stable reactor operation with the AOB and NOB population accounting for over 80% of the 105 
microbial community with almost 100% conversion of NH4+ to NO3-. The mixed liquor volatile 106 
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suspended solids (MLVSS) concentration was stable at 1437.6 ± 112.9 mg L-1 (mean and 107 
standard errors, respectively, n=10). According to the microbial community analysis with 108 
fluorescence in situ hybridization (FISH) (Law et al., 2011), ammonia-oxidizing beta-109 
proteobacteria accounted for 46 ± 6% (n=20) of the bacterial populations and the Nitrospira 110 
genera (nitrite oxidizers) constituted 38 ± 5% (n=20) of the bacterial populations.  111 
 112 
2.3 Batch experiments 113 
All batch experiments were conducted in 4 L beakers coupled with PLC controllers. 114 
Enriched nitrifying biomass was withdrawn from the SBR during aeration phase when 115 
ammonium was almost depleted. The biomass was added into the beaker to obtain the MLVSS 116 
concentration of approximately 1000 mg L-1 at the beginning of the batch tests. All the batch 117 
experiments were divided into two series according to the initial acyclovir concentration. High 118 
concentration (15 mg L-1) was selected to identify any possible biotransformation products and 119 
elucidate the biotransformation pathways while low concentration (15 µg L-1) was used to study 120 
its degradation profile and verify the biotransformation products under environmentally relevant 121 
concentration. For each concentration level, different sets of experiments were performed (in 122 
duplicates for each experiment) (Table 1). EXP1 was conducted to assess biodegradation of 123 
acyclovir in the presence of ammonium. The constant ammonium concentration (50 mg L-1) was 124 
provided by automatically adding a mixture of ammonium bicarbonate and sodium bicarbonate, 125 
which was controlled by PLC as a pH adjustment process. The adding volume was controlled to 126 
be minor, which would not change the total volume significantly. EXP2 was performed in the 127 
absence of ammonium during the overall time course. EXP3 was carried out with the initial 128 
addition of allylthiourea (ATU), which could inhibit ammonia oxidation probably by chelating 129 
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the copper of AMO active site (Ginestet et al., 1998). The control experiments, EXP4 and EXP5, 130 
were used to assess the contribution of abiotic degradation and hydrolytic degradation to 131 
acyclovir losses using NaN3 and pure water (without biomass), respectively. NaN3 was a 132 
chemical inhibitor used for the inactivation of microbial activities (Rattier et al., 2014). Aerobic 133 
conditions were achieved with controlled air supply to obtain DO concentration of 2.5-3.0 mg L-1. 134 
The pH was maintained in the range of 7.5-8.0 during the time course in all tests. Mixed liquor 135 
samples were taken periodically and immediately frozen until analysis. 136 
 137 
2.4 Sample preparation and chemical analysis 138 
For experiments at initial acyclovir concentration of 15 mg L-1, samples were centrifuged at 139 
12000 g for 5 min without filtration to obtain 1 mL supernatant for further direct structural 140 
elucidation of the biotransformation products and quantification. For experiments at initial 141 
acyclovir concentration of 15 µg L-1, the samples were concentrated through solid phase 142 
extraction (SPE) with vacuum manifold (J. T. Baker, The Netherlands) with the recovery for 143 
acyclovir of 87.2 ± 6.4% (n=3, 10 µg L-1 added). 50 mL samples were first centrifuged at 14000 144 
rpm for 5 min. The supernatant was flowing through Oasis HLB cartridges (6 mL, 200 mg, 145 
Waters, USA) at a rate of 5 mL min-1 after conditioned with 10 mL methanol and 10 mL Milli-Q 146 
water. Then cartridges were dried under vacuum for 30 min before they were eluted with 10 mL 147 
methanol and 10 mL of hexane/acetone (50:50, v/v). The extracted elutes were evaporated to 148 
dryness under gentle nitrogen stream. The residue was reconstituted in 250 µL methanol and 750 149 
µL Mmilli-Q water with 20 µL acyclovir-d4 (internal standard) added before further analysis. 150 
The samples were analyzed by the ultra-fast liquid chromatography (UFLC) (Shimadzu, 151 
Japan) coupled with a 4000 QTRAP hybrid triple quadruple-linear ion trap mass spectrometer 152 
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(QqLIT-MS) equipped with a Turbo Ion Spray source (Applied Biosystems-Sciex, USA). 153 
Chromatographic separation was carried out with the injection volume of 20 µL using an Alltima 154 
C18 column (Alltech Associates Inc., USA) at 40 °C. The mobile phase contained (A) H2O and 155 
(B) CH3CN at a flow rate of 1 mL min-1. The gradient of (B) was conducted as follows: it was 156 
linearly increased to 5% B after 0.5 min, further increased to 20% B for 12.5 min, increased to 157 
50% B within 5 min, increased to 100% B for 2 min, kept constant for 4 min and finally was 158 
decreased to 5% B for 1 min. The total running time including the conditioning of the column to 159 
the initial conditions was 27 min. Positive electrospray ionization (ESI+) mode was applied with 160 
the corresponding parameters: drying gas temperature of 500 °C, drying gas 50 psi, curtain gas 161 
30 psi, spraying gas 50 psi. Tentative structures of biotransformation products were identified 162 
using the full scan mode at a declustering potential of 80 V and mass range of 50-300 amu 163 
followed by the product ion scan mode (MS2) and sequential fragmentation using the ion trap. 164 
Concentrations of acyclovir and its biotransformation product were analyzed in the multiple 165 
reaction monitoring (MRM) mode with two transition ions for confirmation and quantification, 166 
respectively. The samples from the experiments at initial 15 mg L-1 acyclovir need to be diluted 167 
100 times in methanol/Milli-Q water (25:75, v/v) prior to quantification. More detailed 168 
information could be obtained in Table S1 in the supporting information (SI).  169 
Ammonium (NH4+-N) concentrations controlled in the batch biodegradation experiments 170 
were measured with a Lachat QuikChem8000 Flow Injection Analyzer (Lachat Instrument, 171 
Milwaukee) and were shown in Figure S1 in SI. Nitrite was not accumulated significantly with 172 
the concentration lower than 1 mg L-1 for the experimental period and same nitrate concentration 173 
was observed as the SBR effluent (up to 1000 mg L-1). 174 
 175 
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3. Results 176 
 177 
3.1 Control experiments 178 
The sorption ability of acyclovir onto the biomass was considered negligible due to the low 179 
value of octanol-water partition coefficient (Log Kow, -1.59) (Kasim et al., 2004), which could 180 
also be observed from the control experimental results in this study. Regardless of the initial 181 
concentration of acyclovir, both abiotic control (EXP4) and hydrolytic control (EXP5) 182 
experiments demonstrated the stability of acyclovir over the time course without any 183 
transformation products (Figure S2). Sorption and hydrolysis would not contribute to acyclovir 184 
removal. Given that the reactors were covered with aluminum foil from photodegradation, 185 
biodegradation by nitrifying biomass was the major pathway for acyclovir removal in all the 186 
experiments.  187 
 188 
3.2 Acyclovir biodegradation in the presence of ammonium 189 
The removal efficiency, transformation efficiency and degradation constant of acyclovir in 190 
all the biodegradation experiments were summarized in Table 2. Figure 1 shows the results from 191 
the biodegradation experiments in the presence of ammonium. The decrease of acyclovir and 192 
formation of the product were plotted using their respective concentrations normalized to the 193 
initial acyclovir concentration. At initial concentration of 15 mg L-1, acyclovir underwent a 194 
gradual decrease with approximately 65.1% removal at the end of experiments (Figure 1A). 195 
After careful screening in the full scan chromatogram followed by spectrum analysis based on 196 
nitrogen rule and the existence of the peak [m+Na], etc, one major biotransformation product 197 
P239 was found at retention time of 4.88 min (data not shown) with nominal mass of 239. Its 198 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10 
structural elucidation was carried out in the following section 3.5. With the available reference 199 
standard (carboxy-acyclovir), it was increased gradually from the beginning of the experiments 200 
to 6.95 mg L-1 (58.6% of conversion rate) at 240 h. 201 
At initial 15 µg L-1 concentration, the removal efficiency for acyclovir (88.2%) was higher 202 
than that obtained at higher initial level (65.1%) (Figure 1B). The same major product P239 was 203 
continuously increased to 5.74 µg L-1. Only 33.0% of the removed parent compound was 204 
transformed to P239 while the remaining might be transformed to other minor products or 205 
mineralized. 206 
For both initial concentration levels, acyclovir biodegradation followed the pseudo first 207 
order degradation kinetics (Figure S3). Same as their concentration profiles, acyclovir also 208 
showed the higher degradation constant (0.0071 L gVSS-1 h-1) at initial 15 µg L-1 concentration 209 
than 0.0034 L gVSS-1 h-1 at 15 mg L-1 concentration. These degradation constants were lower than 210 
the reported value (4.9 L gSS-1 d-1) (Prasse et al., 2011), probably due to unaccustomed sludge to 211 
acyclovir. Long-term adaption to pharmaceuticals would enhance the degradation ability of the 212 
activated sludge (Pomiès et al., 2015). The decreasing ammonia oxidation rate observed during 213 
the experimental period (Figure 2A) might be due to the inhibition of acyclovir or its 214 
transformation product (Radniechi et al., 2008; Sathyamoorthy et al., 2013), which could lead to 215 
decreasing rates of both substrates. NOB has been proved to be not associated with 216 
pharmaceutical (e.g., atenolol) degradation in previous work, with AMO as the main responsible 217 
of the cometabolism (Fernandez-Fontaina et al., 2012; Sathyamoorthy et al., 2013; Xu et al., 218 
2016). Regardless of initial acyclovir concentration, the positive relationship between acyclovir 219 
degradation rate and ammonia oxidation rate suggested the cometabolic biodegradation of 220 
acyclovir by AOB in the presence of ammonium (Figure 2B). The cometabolism also applies to 221 
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higher concentration of non-growth substrate although it was in the range of the growth substrate 222 
concentration (Quintana et al., 2005). 223 
 224 
3.3 Acyclovir biodegradation in the absence of ammonium  225 
Without the presence of growth substrate, acyclovir was removed by enriched nitrifying 226 
biomass up to 40.9% with the final concentration being 8.5 mg L-1 for the higher initial acyclovir 227 
concentration experiments (Figure 3A). Simultaneously, the product P239 showed a rapid 228 
growing profile compared with the results from experiments with ammonia oxidation. Its 229 
concentration was quantified as 8.7 mg L-1 at 240 h. Nearly constant mass balance during the 230 
time course indicated that almost all the acyclovir removed in the absence of ammonium was 231 
transformed to P239. Furthermore, the mass balance did not show a decreasing trend even after 232 
15 d. Thus, P239 might be the only biotransformation product. 233 
For the low initial acyclovir experiments, the removal rate of acyclovir only reached up to 234 
47.8% without ammonia oxidation, which was significantly lower than that observed in the 235 
presence of ammonium (88.2%) (Figure 3B). Regardless of the initial acyclovir concentration, 236 
the cometabolism in the obligatory presence of growth substrate played a positive role in 237 
degrading acyclovir than the metabolic degradation without ammonia oxidation. The formation 238 
of P239 showed a slower increasing trend compared to that observed in the high initial acyclovir 239 
concentration experiments.  240 
The linear regression on the concentration profiles of acyclovir in Figures S4A and B 241 
demonstrated the constant degradation rate of acyclovir in the biodegradation experiments 242 
without ammonia oxidation. Acyclovir degradation rates during the higher initial concentration 243 
and lower initial concentration experiments were 0.027 mg gVSS-1 h-1 and 0.043 µg gVSS-1 h-1, 244 
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respectively, which were lower than their corresponding degradation rates (0.051, 0.046, 0.042, 245 
0.038, 0.034, 0.031, 0.028 mg gVSS-1 h-1 and 0.18, 0.15, 0.12, 0.090, 0.071, 0.056, 0.044 µg gVSS-1 246 
h-1 at time 0, 24, 48, 72, 96, 120, 144 h) under higher ammonia oxidation rates in the experiments 247 
in the presence of ammonium, further confirmed the important role of cometabolic 248 
biodegradation by AOB for acyclovir removal.  249 
 250 
3.4 Acyclovir biodegradation with ATU inhibition  251 
ATU was added at the beginning of the experiments in order to inhibit the nitrifying 252 
activities of AOB, thus likely leading to the exclusive degradation of acyclovir by heterotrophs. 253 
As no external organic source was provided in the experiments, acyclovir degradation might 254 
attribute to heterotrophic metabolic activity. Figure 4A illustrates that acyclovir experienced a 255 
slow gradual decrease with a removal rate of 36.2% over the experimental period at the higher 256 
initial concentration, which was slightly lower than 40.9% obtained in the absence of 257 
ammonium. P239 was still the only product formed with the concentration increasing to 6.4 mg 258 
L-1 when nitrifying activities were inhibited. Practically 94.1% of the consumed acyclovir was 259 
transformed to P239 and the mass balance leveled off for the overall time course. Therefore, no 260 
other major products might be formed by heterotrophs.  261 
As shown in Figure 4B, acyclovir at initial 15 µg L-1 also declined gradually with a removal 262 
efficiency of 50.3% accompanied by the continuous increase of its product P239 (4.9 µg L-1 at 263 
240 h). The mass balance analysis also indicated the constant mass during the experimental 264 
period with only one product P239 formed.  265 
The linear regression in Figures S4C and D showed acyclovir degradation constants for 266 
experiments at the higher initial concentration and the lower initial concentration were calculated 267 
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as 0.02 mg gVSS-1 h-1 and 0.018 µg gVSS-1 h-1, respectively. Compared to the values obtained in 268 
the absence of ammonium, heterotrophs played a major contribution to acyclovir degradation 269 
under the condition without ammonia oxidation by AOB. The role of AOB and heterotrophs has 270 
been investigated in previous studies on pharmaceutical biodegradation (Khunjar et al., 2011; 271 
Tran et al., 2013). The fact that the same biotransformation products for 17β-ethinylestradiol 272 
were formed by AOB or heterotrophs (Khunjar et al., 2011) was consistent to the observations in 273 
this study. The results confirmed that P239 was the major biotransformation product of acyclovir 274 
by the enriched culture independent on its initial concentration. 275 
 276 
3.5 Structural elucidation of biotransformation product 277 
The full scan chromatogram of the samples indicated the formation of the product P239 278 
during all biodegradation experiments. Its structure was then identified through the analysis and 279 
comparison of the product ion (MS2) spectrum of the biodegradation samples with that of the 280 
available standard carboxy-acyclovir. Figure 5 showed the MS2 spectrum of the molecular ion 281 
m/z 240, which was the protonated P239. The most abundant fragment ions were m/z 152 and 282 
135. The molecular ion m/z 240 underwent the loss of 88 Da to produce the fragment ion m/z 152. 283 
Further fragmentation of m/z 152 led to a loss of NH3 molecule to form m/z 135. The similar 284 
fragmentation pattern was previously reported in the literature (Prasse et al., 2011). Another 285 
minor fragmentation pathway was to form m/z 122 with a loss of 44 Da from m/z 164, following 286 
the loss of 76 Da from molecular ion m/z 240. Collision induced dissociation of the molecular 287 
ion m/z 240 could lead to the third route to obtain the fragment ion m/z 61, via the formation of 288 
the fragment ion 89. There were no further fragmentation pathways from the lowest m/z 61. The 289 
same fragment ions and fragment pattern observed in the standard solution further confirmed that 290 
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P239 could be assigned to 9-carboxymethoxymethylguaine (carboxy-acyclovir) (Figure S5). 291 
The same fragment ions m/z 152 and 135 were also formed in the MS2 spectrums of the 292 
parent compound acyclovir, except m/z 164 and 122, which were also reported in previous 293 
literature (Prasse et al., 2011). The only difference between acyclovir and P239 was the third 294 
pathway forming m/z 75 and m/z 89, respectively (Figure S6), which was attributed to the 295 
oxidation of the hydroxyl group to the carboxy group. This also supported the structural 296 
identification of P239 in this work. 297 
 298 
4. Discussion 299 
In this work, the biodegradation of the antiviral drug acyclovir by an enriched nitrifying 300 
culture was investigated during ammonia oxidation and without the addition of ammonium. 301 
Acyclovir degradation rates based on pseudo first order kinetics under higher ammonia oxidation 302 
rate in the presence of ammonium were higher than those constant values in the absence of 303 
ammonium. The positive correlation observed between acyclovir degradation rate and ammonia 304 
oxidation rate further confirmed the cometabolism of acyclovir by the enriched nitrifying culture 305 
in the presence of ammonium, which was also supported from the similar relationship for 17α-306 
ethinylestradiol (Yi and Harper, 2007). 307 
Based on the identified product, the main biotransformation pathway was proposed for 308 
acyclovir degradation: from acyclovir to carboxy-acyclovir (P239). This reaction was attributed 309 
to the oxidation of the terminal hydroxyl group to the carboxy group, which was typically 310 
catalyzed by AMO from AOB or ammonia oxidizing archaea (AOA) for most pharmaceuticals 311 
including other antiviral drugs (abacavir, emtricitabine, ganciclovir, lamivudine and zidovudine), 312 
amide-containing compounds (e.g. propachlor) and tertiary amines such as mianserin (Funke et 313 
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al., 2016; Helbling et al., 2010; Men et al., 2016). Although it was also observed in mammalian 314 
metabolism of acyclovir (Prasse et al., 2011), the enzyme-induced alcohol oxidation has not been 315 
investigated solely for heterotrophs previously. However, the formation of carboxy-acyclovir in 316 
experiments with ATU addition in this work indicated that the monooxygenase from 317 
heterotrophs could also catalyze the alcohol oxidation of such compound. Although other 318 
possibly formed products were not identified in the presence of ammonium, the same 319 
biotransformation product carboxy-acyclovir found with ammonia oxidation and with 320 
nitrification inhibited in this study was different from previous report on iopromide, where 321 
dehydroxylated and carboxylated products were formed, respectively (Batt et al., 2006). It was 322 
proposed that oxidation of acyclovir to carboxy-acyclovir might be catalyzed by monooxygenase 323 
from either AOB or heterotrophs (Men et al., 2016). 324 
It was also noted that the formation of carboxy-acyclovir was independent on the metabolic 325 
type, i.e. regardless of the presence of ammonia oxidation by AOB. This was contradictory to the 326 
observation that the generation of 4-chlorobenzoic acid was related to the metabolic type and 327 
only produced by microbial hydrolysis of the amide bond of bezafibrate under cometabolism 328 
(Quintana et al., 2005). Comparing with acyclovir, the human metabolite carboxy-ibuprofen was 329 
not found in biodegradation of ibuprofen following alcohol oxidation (Quintana et al., 2005). 330 
The possible reason could be related to the specific structures of the studied pharmaceuticals. 331 
The guanine group of acyclovir showed no significant changes during biodegradation with the 332 
primary hydroxyl being the only vulnerable group. However, whether acyclovir could be 333 
biotransformed to other products is not confirmed in the product identification in this study 334 
although the mass balance analysis in the presence of ammonium demonstrated the possible 335 
formation of other products. Further work would be required to confirm the thorough 336 
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biotransformation pathway of acyclovir. 337 
The biotransformation pathway to carboxy-acyclovir by enriched nitrifying cultures was 338 
independent of the initial concentration of acyclovir, i.e. 15 µg L-1 or 15 mg L-1. This was in 339 
consistent with the previous study on trimethoprim by nitrifying activated sludge (Eichhorn et 340 
al., 2005). Two metabolites were formed and the degradation route was independent on the 341 
initial concentration of trimethoprim (20 mg L-1 or 20 µg L-1). However, biodegradation of 342 
trimethoprim was also investigated by nitrifying activated sludge in another recent study (Jewell 343 
et al., 2016), resulting in different biotransformation products under different spiked 344 
concentration of trimethoprim (500 µg L-1 or 5 µg L-1). From the mass balance analysis, carboxy-345 
acyclovir seems to be the only product by heterotrophs either in higher initial concentration or 346 
lower initial concentration of acyclovir. There might be other minor biotransformation products 347 
formed through cometabolism by enriched nitrifying cultures as carboxy-acyclovir had a low 348 
final percentage and the total mass showed a decreasing trend, which was vastly different from 349 
those under other conditions (in the absence of ammonium and with addition of ATU), which 350 
could not be confirmed yet currently and required future efforts. 351 
 352 
5. Conclusion 353 
Biodegradation of acyclovir by an enriched nitrifying culture was investigated during 354 
ammonia oxidation and without the presence of ammonium at different initial concentrations of 355 
acyclovir in this study. The key conclusions are: 356 
• Biodegradation of acyclovir was positively related to the ammonia oxidation rate, confirmed 357 
the key role of cometabolism by AOB in acyclovir removal. 358 
• Carboxy-acyclovir was produced from acyclovir regardless of the presence of ammonium 359 
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and thus unaffected by metabolic type. 360 
• The same biotransformation pathway from acyclovir to carboxy-acyclovir was observed at 361 
different initial concentrations of acyclovir. 362 
• Alcohol oxidation was the biotransformation reaction catalyzed by non-specific enzyme 363 
monooxygenase, probably either from AOB or heterotrophs. 364 
 365 
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Table and figure legends 480 
 481 
Table 1. Conditions of conducted batch experiments with acyclovir (same design of key 482 
experimental conditions for experiments at initial acyclovir of 15 mg L-1 and 15 µg L-1) 483 
 484 
Table 2. The acyclovir removal efficiency, biotransformation efficiency and degradation 485 
constant in the conducted biodegradation experiments (high, initial acyclovir concentration of 15 486 
mg L-1; low, initial acyclovir concentration of 15 µg L-1) with possible mechanisms involved 487 
 488 
Figure 1. Concentration profiles of acyclovir and its product normalized to the initial acyclovir 489 
of (A) 15 mg L-1 and (B) 15 µg L-1 in the experiments with ammonia oxidation. 490 
 491 
Figure 2. (A) Ammonia oxidation rate during the time course in the acyclovir biodegradation 492 
experiments with ammonia oxidation; (B) the relationship between acyclovir degradation rate 493 
and ammonia oxidation rate in the presence of ammonium. 494 
 495 
Figure 3. Concentration profiles of acyclovir and its product normalized to the initial (A) 15 mg 496 
L-1 and (B) 15 µg L-1 in the experiments without ammonia addition. 497 
 498 
Figure 4. Concentration profiles of acyclovir and its product normalized to the initial (A) 15 mg 499 
L-1 and (B) 15 µg L-1 in the experiments with inhibition of ammonia oxidation of AOB by 500 
allythiourea (ATU) addition. 501 
 502 
Figure 5. The fragmentation pathways of P239 under ESI+ conditions derived from MS2 503 
experiments in the QqLIT mass spectrometer. 504 
505 
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Table 1. Conditions of conducted batch experiments with acyclovir (same design of key 506 
experimental conditions for experiments at initial acyclovir of 15 mg L-1 and 15 µg L-1) 507 
Experiments EXP1 EXP2 EXP3 EXP4 EXP5 
Initial ammonium 
(mg L-1) 
50 0 50 50 50 
Ammonium control Constant 0 Constant Constant Constant 
Approximate VSS 
(mg L-1) 
1000 1000 1000 1000 0 
Volume (L) 4 4 4 4 4 
ATU (mg L-1) 0 0 30 0 0 
NaN3 (mg L-1) 0 0 0 500 0 
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Table 2. The acyclovir removal efficiency, biotransformation efficiency and degradation 508 
constant in the conducted biodegradation experiments (high, initial acyclovir concentration of 15 509 
mg L-1; low, initial acyclovir concentration of 15 µg L-1) with possible mechanisms involved 510 
Experiments EXP1-high EXP1-low EXP2-high EXP2-low EXP3-high EXP3-low 
Removal 
efficiency (%) 
65.1 88.2 40.9 47.8 36.2 50.3 
Biotransformation 
efficiency (%) 
58.6 33.0 ~100 72.6 94.1 83.8 
Biodegradation 
constant 
0.0034 
L gVSS-1 h-1 
0.0071 
L gVSS-1 h-1 
0.027 
mg gVSS-1 h-1 
0.043 
µg gVSS-1 h-1 
0.02 
mg gVSS-1 h-1 
0.018 
µg gVSS-1 h-1 
Main mechanisms Cometabolism by AOB 
Metabolism by AOB and 
heterotrophs 
Metabolism by heterotrophs 
 511 
512 
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Figure 1. Concentration profiles of acyclovir and its product normalized to the initial acyclovir 515 
of (A) 15 mg L-1 and (B) 15 µg L-1 in the experiments with ammonia oxidation. 516 
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Figure 2. (A) Ammonia oxidation rate during the time course in the acyclovir biodegradation 520 
experiments with ammonia oxidation; (B) the relationship between acyclovir degradation rate 521 
and ammonia oxidation rate in the presence of ammonium. 522 
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Figure 3. Concentration profiles of acyclovir and its product normalized to the initial (A) 15 mg 527 
L-1 and (B) 15 µg L-1 in the experiments without ammonia addition. 528 
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 532 
Figure 4. Concentration profiles of acyclovir and its product normalized to the initial (A) 15 mg 533 
L-1 and (B) 15 µg L-1 in the experiments with inhibition of ammonia oxidation of AOB by 534 
allythiourea (ATU) addition. 535 
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 539 
Figure 5. The fragmentation pathways of P239 under ESI+ conditions derived from MS2 540 
experiments in the QqLIT mass spectrometer. 541 
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Highlights 
 Acyclovir biodegradation followed cometabolism by AOB in the presence of ammonium. 
 Alcohol oxidation was the main biotransformation pathway producing carboxy-acyclovir. 
 Formation of carboxy-acyclovir was independent on the initial concentration of acyclovir. 
 Metabolic type has no effect on the biotransformation pathway into carboxy-acyclovir. 
 The enzyme-linked oxidation could be catalyzed by AOB or heterotrophs. 
 
